148 Participants NeededMy employer runs this trial

VX-407 for Oral Contraceptive Interaction

MI
Overseen ByMedical Information
Age: 18 - 65
Sex: Female
Trial Phase: Phase 1
Sponsor: Vertex Pharmaceuticals Incorporated
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.

Are You a Good Fit for This Trial?

This trial is for adults with a BMI between 18 and 30, weighing over 50 kg. Participants are likely women who use oral contraceptives and may have polycystic kidney disease.

Inclusion Criteria

My body weight is over 50 kg.
My BMI is between 18.0 and 30.0.
This is a key eligibility criterion for the study.

What Are the Treatments Tested in This Trial?

Interventions

  • VX-407

Trial Overview

The study tests how the new drug VX-407 affects the way different birth control pills (oral contraceptives) work in the body, as well as its safety when taken together.

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Group I: Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)Experimental Treatment2 Interventions
Group II: Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)Experimental Treatment2 Interventions
Group III: Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)Experimental Treatment2 Interventions
Group IV: Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)Experimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vertex Pharmaceuticals Incorporated

Lead Sponsor

Trials
267
Recruited
36,100+
Dr. David Altshuler profile image

Dr. David Altshuler

Vertex Pharmaceuticals Incorporated

Chief Medical Officer since 2020

MD, PhD

Dr. Reshma Kewalramani profile image

Dr. Reshma Kewalramani

Vertex Pharmaceuticals Incorporated

Chief Executive Officer since 2020

MD, trained in internal medicine and nephrology